(VIANEWS) - Chesapeake Granite Wash Trust (CHKR), Gilead Sciences (GILD), Boston Properties (BXP) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio at the moment. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Chesapeake Granite Wash Trust (CHKR)
100% Payout Ratio
Chesapeake Granite Wash Trust holds royalty rights in natural gas liquids and oil properties in Washita County, in the Anadarko Basin, Western Oklahoma. It holds royalty rights in approximately 26400 acres and has 69 production wells. Its reserves for royalty interests were 2,736 million barrels of equivalent oil of proven developed reserves as of December 31, 2020. Chesapeake Granite Wash Trust, which was established in 2011, is located in Houston.
Earnings per Share
Profitability is Chesapeake Granite Wash Trust's trailing twelve-month EPS at $0.26
PE Ratio
The trailing 12-month price-earnings ratio for Chesapeake Granite Wash Trust is 4.46. The purchaser of the shares is therefore investing $4.46 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 108.07%.2. Gilead Sciences (GILD)
88.07% Payout Ratio
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Earnings Per Share
As for profitability, Gilead Sciences has a trailing twelve months EPS of $0.24.
PE Ratio
Gilead Sciences has a trailing twelve months price to earnings ratio of 353. Meaning, the purchaser of the share is investing $353 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.58%.3. Boston Properties (BXP)
67.59% Payout Ratio
Boston Properties (NYSE.BXP), the nation's largest privately-held developer, is the owner and operator of Class A office buildings in the United States. It has five major markets: Boston, Los Angeles, New York, San Francisco, San Francisco, Washington, DC. As a real-estate investment trust (REIT), the Company can develop, manage, operate, acquire, and maintain a wide range of office spaces, primarily Class A. The Company's portfolio totals 51.2 million square feet and 196 properties, including six properties under construction/redevelopment.
Earnings Per Share
As for profitability, Boston Properties has a trailing twelve months EPS of $2.93.
PE Ratio
Boston Properties has a trailing twelve months price to earnings ratio of 23.33. Meaning, the purchaser of the share is investing $23.33 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.23%.4. MSCI (MSCI)
42.75% Payout Ratio
MSCI Inc., together with its subsidiaries, provides investment decision support tools for the clients to manage their investment processes worldwide. It operates through four segments: Index, Analytics, ESG and Climate, and All Other – Private Assets. The Index segment provides indexes for use in various areas of the investment process, including indexed product creation, such as ETFs, mutual funds, annuities, futures, options, structured products, over-the-counter derivatives; performance benchmarking; portfolio construction and rebalancing; and asset allocation, as well as licenses GICS and GICS Direct. The Analytics segment offers risk management, performance attribution and portfolio management content, application, and service that provides an integrated view of risk and return, and an analysis of market, credit, liquidity, and counterparty risk across asset classes; managed services, including consolidation of client portfolio data from various sources, review and reconciliation of input data and results, and customized reporting; and HedgePlatform to measure, evaluate, and monitor the risk of hedge fund investments. The ESG and Climate segment provides products and services that help institutional investors understand how ESG factors impact the long-term risk and return of their portfolio and individual security-level investments; and data, ratings, research, and tools to help investors navigate increasing regulation. The All Other – Private Assets segment includes real estate market and transaction data, benchmarks, return-analytics, climate assessments and market insights for funds, investors, and managers; business intelligence to real estate owners, managers, developers, and brokers; and offers investment decision support tools for private capital. It serves asset owners and managers, financial intermediaries, wealth managers, real estate professionals, and corporates. MSCI Inc. was incorporated in 1998 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, MSCI has a trailing twelve months EPS of $7.75.
PE Ratio
MSCI has a trailing twelve months price to earnings ratio of 59.85. Meaning, the purchaser of the share is investing $59.85 for every dollar of annual earnings.
Dividend Yield
Morningstar, Inc. has stated that the next dividend payment will be made on November 8, 2022. The forward dividend rate for 2020 is 5, and the forward dividend yield is 1.12%.
Volume
Today's last reported volume for MSCI is 270281 which is 39.79% below its average volume of 448917.